



20 July 2021

Bruce Linton confirms intention to Chair The HighBrid Lab Board of Directors

Highlights:

- **Bruce Linton to Chair the Board of The HighBrid Lab conditional upon shareholder approval and completion of the merger between Creso Pharma and Red Light Holland**
- **Mr Linton was the founder and served as Chairman and CEO of Canopy Growth Corporation – one of the world’s largest cannabis companies**
- **As Chairman and CEO of Canopy Growth, Mr Linton led over 16 rounds of financing, 31 acquisitions, and US\$6Bn of capital raises, including a C\$5Bn investment by Fortune 500 beverage alcohol company, Constellation Brands**
- **The HighBrid Lab to benefit from his deep understanding and industry leading experience within both psychedelics and cannabis sectors to drive growth strategy**

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to advise that cannabis and psychedelics industry veteran Mr Bruce Linton has confirmed that he will join the HighBrid Lab Board of Directors as Chairman, conditional upon shareholder approval and the completion of the merger between Creso Pharma and Red Light Holland Corp. (**Red Light Holland'**) (refer ASX announcement: 17 June 2021).

Mr Linton has a passion for entrepreneurship and making a positive difference in the world. He brings a wealth of experience in building strong technology-driven companies, developing world-class teams, and positioning his companies in sectors driven by waves of public policy change. Mr Linton is the founder and served as the Chairman and CEO of Canopy Growth Corporation (Nasdaq:CGC, TMX:WEED). As Chairman and CEO of Canopy Growth Corporation, Mr Linton led the company through over 16 rounds of financing, 31 acquisitions, and US\$6 billion of capital raises, including a C\$5 billion investment by Fortune 500 beverage alcohol company, Constellation Brands.

Subject to the closing of the merger between Creso Pharma and Red Light Holland and the required shareholder approval, Mr Linton, in his capacity as non-executive Chairman of The HighBrid Lab, will leverage his deep understanding and industry leading experience within both psychedelics and cannabis to support the senior management team as it executes on The HighBrid Lab's defined growth strategies across all business units.

Commentary:

Incoming Chairman of The HighBrid Lab, Bruce Linton said: *"I'm really excited about the opportunity to work even more closely with The HighBrid Lab upon closing of the Creso Pharma and Red Light Holland merger. The combined company has tremendous optionality to capitalise on several high growth, nascent verticals.*

"Additionally, having worked with key team members in the past, I'm confident that the HighBrid Lab's prospects for growth through both decisive M&A and organic growth is extremely exciting."

Creso Pharma Non-Executive Chairman Adam Blumenthal said: *"We are very excited to have Bruce commit to his position as Chairman of The HighBrid Lab. Bruce has extensive expertise in the cannabis*



and psychedelic areas, as well as an unparalleled network, which will be imperative in the combined company's growth trajectory.

"We continue to work closely with Red Light Holland's management team to gain a strong understanding of Red Light Holland's operations, as well as additional synergies between the businesses. We anticipate that further developments across product development and sales channels will be made in the coming months, which will unlock further value for our shareholders."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Forward Looking Statements

This announcement contains forward-looking statements with respect to Creso Pharma and its respective operations, strategy, investments, financial performance and condition. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Creso Pharma or its subsidiaries to be materially



different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this announcement. Examples of such information include statements with respect to the anticipated benefits and synergies of the merger between Creso Pharma and Red Light Holland including with respect to product development and sales channels, The HighBrid Lab's growth trajectory, the proposed board of directors of The HighBrid Lab and expectations of developments in product development and sales channels of Creso Pharma. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals and satisfy the other conditions to complete the merger; the prompt and effective integration of the businesses and the ability to achieve the anticipated benefits contemplated by the transaction; expectations regarding future investment, growth and expansion of the operations of the businesses; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; risks related to infectious diseases, including the impacts of the COVID-19 pandemic; legal and regulatory risks inherent in the cannabis and magic psychedelics industries, including the global regulatory landscape and enforcement related to cannabis and psychedelics, political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis and psychedelics industries; and such other risks contained in the public filings of Creso Pharma filed with Australian securities regulators. The cautionary statements qualify all forward-looking statements attributable to Creso Pharma and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso Pharma has no obligation to up-date such statements, except to the extent required by applicable laws.